.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,985,869

« Back to Dashboard

Details for Patent: 5,985,869

Title: Benzoheterocyclic compounds
Abstract:Novel benzoheterocyclic compounds of the formula: ##STR1## wherein R.sup.1 is H, halogen, alkyl, optionally substituted amino, alkoxy; R.sup.2 is H, halogen, alkoxy, phenylalkoxy, OH, alkyl, optionally substituted amino, carbamoyl-alkoxy, optionally substituted amino-alkoxy, optionally substituted benzoyloxy; R.sup.3 is a group: --NR.sup.4 R.sup.5 or --CO--NR.sup.11 R.sup.12 ; R.sup.4 is H, optionally substitued benzoyl, alkyl; R.sup.5 is a group: ##STR2## [R.sup.16 is halogen, optionally substituted alkyl, OH, alkoxy, alkanoyloxy, alkylthio, alkanoyl, carboxy, alkoxycarbonyl, CN, NO.sub.2, optionally substituted amino, phenyl, cycloalkyl, etc., or a group: --O--A--NR.sup.6 R.sup.7 ; m is 0 to 3], phenyl-alkoxycarbonyl, alkanoyl, phenylalkanoyl, etc.; R.sup.11 is H or alkyl; R.sup.12 is cycloalkyl or optionally substituted phenyl; and W is a group: --(CH.sub.2).sub.p (p is 3 to 5) or --CH.dbd.CH--(CH.sub.2).sub.q (q is 1 to 3), the carbon atom of these groups beign optionally replaced by O, S, SO, SO.sub.2 or a group: --N(R.sup.13)-- and further these groups having optionally 1 to 3 substituents of alkyl, alkoxycarbonyl, carboxy, OH, O, alkanoyloxy, etc., which have excellent vasopressin antagonistic activities and are useful as vasodilator, hypotensive agent, water diuretics, platelet agglutination inhibitor, and a vasopressin antagonistic composition containing the compound as the active ingredient.
Inventor(s): Ogawa; Hidenori (Tokushima-ken, JP), Miyamoto; Hisashi (Kyoto-fu, JP), Kondo; Kazumi (Tokushima-ken, JP), Yamashita; Hiroshi (Tokushima-ken, JP), Nakaya; Kenji (Tokushima-ken, JP), Komatsu; Hajime (Tokushima-ken, JP), Tanaka; Michinori (Tokushima-ken, JP), Kora; Shinya (Nagasaki-ken, JP), Tominaga; Michiaki (Tokushima-ken, JP), Yabuuchi; Yoichi (Tokushima-ken, JP)
Assignee: Otsuka Pharmaceutical Company, Limited (Tokyo, JP)
Filing Date:Jul 15, 1997
Application Number:08/893,925
Claims:1. A method for antagonizing vasopressin which comprises administering to a subject a therapeutically effective amount of a benzoheterocyclic compound of the formula: ##STR2516## wherein R.sup.1 is a hydrogen atom, a halogen atom, a C.sub.1 -C.sub.6 alkyl, an amino having optionally a C.sub.1 -C.sub.6 alkyl substituent, or a C.sub.1 -C.sub.6 alkoxy;

R.sup.2 is a hydrogen atom, a halogen atom, a C.sub.1 -C.sub.6 alkoxy, a phenyl-(C.sub.1 -C.sub.6) alkoxy, hydroxy, a C.sub.1 -C.sub.6 alkyl, an amino having optionally a C.sub.1 -C.sub.6 alkyl substituent, a carbamoyl-substituted C.sub.1 -C.sub.6 alkoxy, an amino-substituted C.sub.1 -C.sub.6 alkoxy having optionally a C.sub.1 -C.sub.6 alkyl substituent, or a benzoyloxy which has optionally a halogen substituent on the phenyl ring;

R.sup.3 is a group of the formula: ##STR2517## or a group of the formula: ##STR2518## R.sup.4 is a hydrogen atom, a benzoyl which has optionally a halogen substituent on the phenyl ring or a C.sub.1 -C.sub.6 alkyl;

R.sup.5 is a group of the formula: ##STR2519## wherein R.sup.16 is a halogen atom, a C.sub.1 -C.sub.6 alkyl which has optionally a substituent selected from a halogen atom and hydroxy, hydroxy, a C.sub.1 -C.sub.6 alkoxy, a C.sub.1 -C.sub.6 alkanoyloxy, a C.sub.1 -C.sub.6 alkylthio, a C.sub.1 -C.sub.6 alkanoyl, carboxy, a C.sub.1 -C.sub.6 alkoxycarbonyl, a cyano; a nitro, an amino which has optionally a substituent selected from a C.sub.1 -C.sub.6 alkyl and a C.sub.1 -C.sub.6 alkanoyl, a phenyl, a C.sub.3 -C.sub.8 cycloalkyl, a C.sub.2 -C.sub.6 alkanoyloxy-substituted C.sub.1 -C.sub.6 alkoxy, a carboxy-substituted C.sub.1 -C.sub.6 alkoxy, a halogen-substituted C.sub.1 -C.sub.6 alkoxy, a carbamoyl-substituted C.sub.1 -C.sub.6 alkoxy, a hydroxy-substituted C.sub.1 -C.sub.6 alkoxy, a C.sub.1 -C.sub.6 alkoxycarbonyl-substituted C.sub.1 -C.sub.6 alkoxy, a phthalimido-substituted C.sub.1 -C.sub.6 alkoxy; an aminocarbonyl-(C.sub.1 -C.sub.6) alkoxy having a C.sub.1 -C.sub.6 alkyl substituent; or a group of the formula: ##STR2520## wherein A is a C.sub.1 -C.sub.6 alkylene, and R.sup.6 and R.sup.7 are the same or different and are each a hydrogen atom, a C.sub.1 -C.sub.6 alkyl having optionally a hydroxy substituent, a C.sub.1 -C.sub.6 alkanoyl or benzoyl, or R.sup.6 and R.sup.7 may bind together with the nitrogen atom to which they are bonded to form a 5- or 6-membered saturated heterocyclic group with or without an intervening nitrogen or oxygen atom wherein the heterocyclic group is one member selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl and morpholino, and has optionally a substituent selected from piperidinyl and a C.sub.1 -C.sub.6 alkyl; and m is an integer of 0 to 3, or

R.sup.5 is a phenyl-(C.sub.1 -C.sub.6) alkoxycarbonyl, a C.sub.1 -C.sub.6 alkanoyl, a phenyl-(C.sub.2 -C.sub.6) alkanoyl, a C.sub.3 -C.sub.8 cycloalkyl-(C.sub.2 -C.sub.6) alkanoyl, a C.sub.3 -C.sub.8 cycloalkylcarbonyl, tricyclo(3.3.1.1)decanylcarbonyl, naphthylcarbonyl, pyridylcarbonyl, fulroyl, thenoyl, a phenoxy-(C.sub.2 -C.sub.6) alkanoyl which phenyl ring has optionally 1 to 3 substituents selected from a C.sub.1 -C.sub.6 alkyl, a C.sub.1 -C.sub.6 alkoxy and an amino having optionally a C.sub.1 -C.sub.6 alkanoyl substituent, a phthalimido-substituted C.sub.2 -C.sub.6 alkanoyl, a C.sub.1 -C.sub.6 alkoxycarbonyl-(C.sub.2 -C.sub.6) alkanoyl, a carboxy-(C.sub.2 -C.sub.6) alkanoyl, a naphthyloxy-(C.sub.2 -C.sub.6) alkanoyl, a halogen-substituted C.sub.1 -C.sub.6 alkanoyl, a group of the formula: ##STR2521## wherein R.sup.8 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl, a phenyl-(C.sub.1 -C.sub.6) alkoxycarbonyl, a carbamoyl-(C.sub.1 -C.sub.6) alkyl, an amino-(C.sub.2 -C.sub.6) alkanoyl having optionally a C.sub.1 -C.sub.6 alkyl substituent, or a C.sub.1 -C.sub.6 alkanoyl, an anilinocarbonyl which has optionally a C.sub.1 -C.sub.6 alkyl substituent on the phenyl ring, phenoxycarbonyl, a phenylsulfonyl which has optionally a substituent selected from a halogen atom and a C.sub.1 -C.sub.6 alkyl on the phenyl ring, quinolylsulfonyl, or a group of the formula: ##STR2522## wherein B is a C.sub.1 -C.sub.6 alkylene, n is an integer of 0 or 1, and R.sup.9 and R.sup.10 are the same or different and are each a hydrogen atom, a C.sub.1 -C.sub.6 alkyl having optionally a hydroxy substituent, a C.sub.3 -C.sub.8 cycloalkyl, a phenyl-(C.sub.1 -C.sub.6) alkyl, a C.sub.1 -C.sub.6 alkanoyl, a C.sub.2 -C.sub.6 alkenyl, a phenoxy-(C.sub.1 -C.sub.6) alkyl, a phenyl which has optionally 1 to 3 substituents selected from an amino-(C.sub.1 -C.sub.6) alkyl having optionally a C.sub.1 -C.sub.6 alkanoyl substituent, a C.sub.1 -C.sub.6 alkyl, a C.sub.1 -C.sub.6 alkoxy and a halogen atom, a phthalimido-substituted C.sub.1 -C.sub.6 alkyl, an amino-(C.sub.1 -C.sub.6) alkyl having optionally a C.sub.1 -C.sub.6 alkanoyl substituent, a C.sub.2 -C.sub.6 alkynyl, or an amino-(C.sub.1 -C.sub.6) alkyl having optionally a C.sub.1 -C.sub.6 alkyl substituent, or R.sup.9 and R.sup.10 may bind together with the nitrogen atom to which they are bonded to form a 5- or 6-membered saturated heterocyclic group with or without being intervened with a nitrogen or an oxygen atom wherein the heterocyclic group is one member selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl and morpholino, and has optionally a substituent selected from a C.sub.1 -C.sub.6 alkyl, a C.sub.1 -C.sub.6 alkoxycarbonyl and piperidinyl,

R.sup.11 is a hydrogen atom or a C.sub.1 -C.sub.6 alkyl,

R.sup.12 is a C.sub.3 -C.sub.8 cycloalkyl, or a phenyl which has optionally 1 to 3 substituents selected from a C.sub.1 -C.sub.6 alkoxy, a C.sub.1 -C.sub.6 alkyl and a halogen atom,

W is a group of the formula: --(CH.sub.2).sub.p -- wherein p is an integer of 3 to 5, or a group of the formula: --CH.dbd.CH--(CH.sub.2).sub.q -- wherein q is an integer of 1 to 3, wherein one of the CH.sub.2 groups associated with the formula CH.sub.2 associated with the --(CH.sub.2).sub.p -- and the --CH.dbd.CH--(CH.sub.2).sub.q -- is replaced by a group of the formula: ##STR2523## wherein R.sup.13 is a hydrogen atom, a C.sub.3 -C.sub.8 cycloalkyl, or a C.sub.1 -C.sub.6 alkyl, and further said --(CH.sub.2).sub.p -- group and said --CH.dbd.CH--(CH.sub.2).sub.q -- group having optionally 1 to 3 substituents selected from a C.sub.1 -C.sub.6 alkyl having optionally a hydroxy substituent, a C.sub.1 -C.sub.6 alkoxycarbonyl, carboxy, hydroxy, oxo, a C.sub.1 -C.sub.6 alkanoyloxy having optionally a halogen substituent, an amino-(C.sub.1 -C.sub.6) alkyl having optionally a substituent selected from a C.sub.1 -C.sub.6 alkyl and a C.sub.1 -C.sub.6 alkanoyl, a C.sub.1 -C.sub.6 alkanoyloxy-substituted C.sub.1 -C.sub.6 alkyl, a C.sub.1 -C.sub.6 alkylsulfonyloxy-(C.sub.1 -C.sub.6) alkyl, an azido-(C.sub.1 -C.sub.6) alkyl, a group of the formula: ##STR2524## an aminocarbonyloxy having optionally a C.sub.1 -C.sub.6 alkyl substituent, a C.sub.1 -C.sub.6 alkoxy, a C.sub.1 -C.sub.6 alkoxycarbonyl-substituted C.sub.1 -C.sub.6 alkoxy, a carboxy-substituted C.sub.1 -C.sub.6 alkoxy, an aminocarbonyl-(C.sub.1 -C.sub.6) alkoxy having optionally a C.sub.1 -C.sub.6 alkyl substituent, an amino-(C.sub.1 -C.sub.6) alkoxy having optionally a substituent selected from a C.sub.1 -C.sub.6 alkyl and a C.sub.1 -C.sub.6 alkanoyl, a phthalimido-substituted C.sub.1 -C.sub.6 alkoxy, hydroxy-imino, a C.sub.1 -C.sub.6 alkanoyloxy-imino, a C.sub.1 -C.sub.6 alkylidene, a halogen atom, azido, sulfoxyimino, a group of the formula: ##STR2525## wherein R.sup.81 is a hydrogen atom or a C.sub.1 -C.sub.6 alkyl, provided that said ##STR2526## binds to said --(CH.sub.2).sub.p -- or said --CH.dbd.CH--(CH.sub.2).sub.q -- to form a 6-membered ring, a group of the formula: ##STR2527## wherein A is as defined above in this claim, and R.sup.82 and R.sup.83 are the same or different and are each a hydrogen atom, a C.sub.1 -C.sub.6 alkyl, a carbamoyl-substituted C.sub.1 -C.sub.6 alkyl, a hydroxy-substituted C.sub.1 -C.sub.6 alkyl, or a pyridyl-(C.sub.1 -C.sub.6) alkyl, or R.sup.82 and R.sup.83 may bind together with the nitrogen atom to which they are bonded to form a 5- or 6-membered saturated heterocyclic group with or without being intervened with a nitrogen, oxygen or sulfur atom wherein the heterocyclic group is one member selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl, morpholino, and thiomorpholino, and has optionally a substituent selected from oxo, a C.sub.1 -C.sub.6 alkyl, a C.sub.1 -C.sub.6 alkanoyl, and carbamoyl, and a group of the formula: ##STR2528## wherein n is as defined above in this claim, and R.sup.14 and R.sup.15 are the same or different and are each a hydrogen atom, a C.sub.1 -C.sub.6 alkyl, a C.sub.2 -C.sub.6 alkenyl, a C.sub.1 -C.sub.6 alkanoyl, a C.sub.3 -C.sub.8 cycloalkyl, an oxiranyl-substituted C.sub.1 -C.sub.6 alkyl, a C.sub.1 -C.sub.6 alkyl having 1 to 2 substituents selected from a C.sub.1 -C.sub.6 alkoxy, hydroxy and an amino having optionally a C.sub.1 -C.sub.6 alkyl substituent, a phenyl-(C.sub.1 -C.sub.6) alkyl, a pyridyl-(C.sub.1 -C.sub.6) alkyl, a C.sub.1 -C.sub.6 alkylsulfonyl, benzoyl, a C.sub.1 -C.sub.6 alkoxycarbonyl, anilinocarbonyl, an aminocarbonyl having optionally a C.sub.1 -C.sub.6 alkyl substituent, a cyano-substituted C.sub.1 -C.sub.6 alkyl, a C.sub.1 -C.sub.6 alkoxycarbonyl-substituted C.sub.1 -C.sub.6 alkyl, a carbamoyl-substituted C.sub.1 -C.sub.6 alkyl, a carboxy-substituted C.sub.1 -C.sub.6 alkyl, a tetrahydropyranyloxy-substituted C.sub.1 -C.sub.6 alkyl, a C.sub.1 -C.sub.6 alkanoyloxy-substituted C.sub.1 -C.sub.6 alkyl, a piperidinyl having optionally a phenyl-(C.sub.1 -C.sub.6) alkyl substituent on the piperidine ring, a halogen substituted C.sub.1 -C.sub.6 alkanoyl, an imidazolyl-substituted C.sub.2 -C.sub.6 alkanoyl, an amino-(C.sub.2 -C.sub.6) alkanoyl having optionally a substituent selected from a C.sub.1 -C.sub.6 alkyl and a C.sub.1 -C.sub.6 alkoxycarbonyl, an aminocarbonyl-(C.sub.1 -C.sub.6) alkyl having optionally a C.sub.1 -C.sub.6 alkyl substituent, or a phenyl-(C.sub.1 -C.sub.6) alkoxycarbonyl, or R.sup.14 or R.sup.15 may bind together with the nitrogen atom to which they are bonded to form a 5- or 6-membered saturated heterocyclic group with or without being intervened with a nitrogen or oxygen atom, wherein the heterocyclic group is one member selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl, and morpholino, and may optionally have a substituent selected from a C.sub.1 -C.sub.6 alkyl, a phenyl-(C.sub.1 -C.sub.6) alkyl or a C.sub.1 -C.sub.6 alkanoyl, and a pharmaceutically acceptable salt thereof.

2. The method according to claim 1, wherein W is a group of the formula: --(CH.sub.2).sub.p -- wherein p is an integer of 3 to 5, and one of the CH.sub.2 groups is replaced by a group of the formula: ##STR2529## wherein R.sup.13 is a hydrogen atom, a C.sub.3 -C.sub.8 cycloalkyl, or a C.sub.1 -C.sub.6 alkyl.

3. The method according to claim 1, wherein W is a group of the formula: --CH.dbd.CH--(CH.sub.2).sub.q -- wherein q is an integer of 1-3 and one of the CH.sub.2 groups is replaced by a group of the formula: ##STR2530## wherein R.sup.13 is a hydrogen atom, a C.sub.3 -C.sub.8 cycloalkyl, or a C.sub.1 -C.sub.6 alkyl.

4. The method according to claim 2, wherein p in the group of the formula: --(CH.sub.2).sub.p -- is 3.

5. The method according to claim 2, wherein p in the group of the formula: --(CH.sub.2).sub.p -- is 4.

6. The method according to claim 2, wherein p in the group of the formula: --(CH.sub.2).sub.p -- is 5.

7. The method according to claim 5, wherein the heterocyclic group of the formula: ##STR2531## is 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine.

8. The method according to claim 1, wherein the benzoheterocyclic compound is 1-[4-(2-mehtylbenzoylamino)benzoyl]-4-methyl-2,3,4,5-tetrahydro-1H-benzodi azepine.

9. The method according to claim 1, wherein the heterocyclic group of the formula: ##STR2532## is 2,3,4,5-tetrahydro-1H-1,5-benzodiazepine.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc